Last reviewed · How we verify
Thalidomide plus dexamethasone
Thalidomide acts as an immunomodulatory agent and cereblon E3 ligase ligand, while dexamethasone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects.
Thalidomide acts as an immunomodulatory agent and cereblon E3 ligase ligand, while dexamethasone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects. Used for Multiple myeloma (newly diagnosed or relapsed/refractory), Light chain myeloma.
At a glance
| Generic name | Thalidomide plus dexamethasone |
|---|---|
| Also known as | Thalomid, Baycadron, DexPak, Decadron |
| Sponsor | Grupo de Estudos Multicentricos em Onco-Hematologia |
| Drug class | Immunomodulatory agent plus corticosteroid |
| Target | Cereblon (CRBN), glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Thalidomide binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3 proteins, which enhances T-cell proliferation and NK cell activation while reducing TNF-α production. Dexamethasone amplifies these effects through glucocorticoid receptor signaling, providing additional anti-inflammatory activity and enhancing apoptosis in malignant cells. This combination is particularly effective in multiple myeloma and other hematologic malignancies.
Approved indications
- Multiple myeloma (newly diagnosed or relapsed/refractory)
- Light chain myeloma
Common side effects
- Peripheral neuropathy
- Thromboembolism
- Infection
- Hyperglycemia
- Fatigue
- Constipation
- Rash
Key clinical trials
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (PHASE4)
- EDOCH Alternating With DHAP for New Diagnosed Younger MCL (PHASE4)
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
- Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (PHASE2)
- ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial (PHASE4)
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma (PHASE3)
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (PHASE2)
- Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |